查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1837454

血液培養檢測市場按產品、最終用戶、技術、檢測類型、應用、樣本類型和模式分類 - 全球預測 2025-2032

Blood Culture Test Market by Product, End User, Technology, Test Type, Application, Sample Type, Mode - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 180 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，血液培養檢測市場規模將達到 73.6 億美元，複合年成長率為 6.36%。

主要市場統計數據
基準年 2024 44.9億美元
預計年份：2025年 47.8億美元
預測年份：2032年 73.6億美元
複合年成長率 (%) 6.36%

簡要說明血液培養診斷在現代醫療保健服務體系中不斷演變的臨床和運作意義

血液培養檢測仍然是診斷血流感染疾病和指導抗菌治療的基本診斷程序。儘管培養系統、自動化和分子輔助技術的進步提高了血液培養工作流程的臨床相關性和操作效率，但實驗室在檢體處理過程中仍需不斷權衡速度、靈敏度和成本。在臨床實踐中，及時檢測能夠直接影響患者的預後，因為它能夠指導標靶治療並減少不必要的抗菌藥物暴露。

同時，實驗室管理人員和採購專業人員必須應對由技術整合、供應鏈動態和不斷變化的監管預期所塑造的全新環境。自動化分析儀與前端檢體處理和資料連接的整合提高了檢測的一致性並縮短了周轉時間，但也引入了新的供應商互通性和驗證方面的考慮。隨著醫療保健系統將診斷管理和實驗室效率置於優先地位，醫院系統、獨立實驗室和門診機構的血液培養檢測正在經歷營運改善和策略重新評估。

本執行摘要概述了目前影響臨床實踐、技術應用和組織投資決策的動態。它重點闡述了診斷範式、政策環境和終端使用者需求的變化如何重塑採購偏好和實施策略，這對臨床實驗室、設備製造商和醫療保健管理者在尋求最佳化整個醫療服務過程中的診斷價值時具有重要意義。

技術創新、自動化、供應鏈韌性和診斷管理如何重塑血液培養檢測的實驗室工作流程和臨床管道

技術創新、工作流程最佳化以及實驗室在診療路徑中角色的重塑，正在改變血液感染的診斷模式。儘管傳統培養技術仍能提供重要的表現型訊息，但分子平台和快速鑑定方法已拓展了臨床醫生的套件，使其能夠更早停止經驗性治療並加強抗菌藥物管理。這種技術變革時期促使實驗室重新評估其檢測流程，並採用培養和分子方法互補的混合方法。

在營運方面，分析前和分析階段自動化程度的不斷提高正在改變實驗室的人員配置模式和處理量預期。自動化減少了人為操作的差異，並支援更高的樣本量，但也需要對培訓、驗證和資訊學進行投資，以確保無縫整合。同時，供應鏈韌性已成為一項策略重點。實驗室和供應商正在探索耗材採購的冗餘方案，並實現物流多元化，以減少中斷風險。

在臨床方面，受支付方審查和機構品質改進舉措的推動，診斷管理日益受到重視。診斷流程正在重新設計，旨在強調及時準確的檢測，同時避免不必要的檢查。這種轉變正在影響自動化和手動檢測方法的應用模式，並凸顯了可操作報告、結果週轉時間和與臨床決策支援系統整合的重要性。總而言之，這些趨勢不僅正在重塑實驗室營運，也為供應商和醫療系統創造了新的合作機會，共同開發能夠帶來可衡量的臨床和經濟價值的整合解決方案。

評估關稅主導的採購壓力因素和供應鏈策略對血液培養診斷整體成本結構、採購決策和分銷模式的影響

近期關稅政策的變化和貿易政策的調整對參與血液培養診斷的臨床實驗室、製造商和經銷商產生了顯著的下游影響。某些檢測設備和耗材進口關稅的提高可能導致到岸成本上升，迫使採購團隊重新評估供應商組合，並協商長期合約以穩定價格。為此，製造商正在考慮生產在地化、替代籌資策略以及產品組合調整，以在維持利潤率的同時減輕關稅的影響。

這些動態將影響終端使用者的採購行為，醫院和獨立實驗室需要在單位成本、供應可靠性和供應商支援承諾之間權衡取捨。有些機構會優先建立關鍵耗材庫存以應對價格波動，而有些機構則會尋求能夠降低資本支出並透過管理服務或租賃協議將供應風險轉移給供應商的服務模式。此外，成本上升可能會加速各機構對自動化和工作流程效率提升措施的興趣，因為他們希望透過節省人事費用和減少浪費來抵消不斷上漲的單位成本。

同時，關稅實施帶來的監管和海關方面的複雜性延長了新型分析儀器和耗材的前置作業時間，並使其上市策略更加複雜。因此，開發商和經銷商正在調整其分銷物流框架，提高整個供應鏈的透明度，並與客戶合作制定緊急時應對計畫。總而言之，這些變化正在推動更具策略性的採購規劃，鼓勵供應商多元化，並獎勵企業投資於供應鏈透明度和在地化生產，以減輕關稅相關成本壓力的累積影響。

綜合細分分析概述了產品、最終用戶、技術、測試類型、應用、樣本類型和模式對產品採納和採購動態的影響。

對產品類型的詳細分析揭示了影響耗材和實驗室設備採購行為的明確因素。耗材，包括試管、培養基和試劑組，是經常性運作成本的主要來源，其評估重點在於批次間一致性、儲存需求以及與自動化系統的兼容性。設備，包括分析儀和自動化系統，則需要進行資本規劃、與實驗室資訊系統整合以及簽訂長期服務合約。因此，採購決策通常需要在耗材供應的可預測性與分析儀部署所帶來的效率提升和檢驗負擔之間取得平衡。

終端使用者細分顯示，門診中心、血庫、診斷實驗室和醫院門診部各自遵循不同的營運模式和採購需求。門診中心通常分為獨立診所和醫生辦公室，其中醫生辦公室優先考慮易用性和占地面積小。血庫優先考慮可靠性和合規性，而診斷實驗室（包括醫院附屬實驗室和獨立實驗室）則優先考慮吞吐量、週轉時間和互通性。在醫院門診部領域，二級和三級醫院需要可擴展的解決方案，其中三級醫院通常會整合先進的識別技術。

傳統方法和分子生物學方法之間的技術選擇決定了診斷途徑。雖然傳統培養仍然是藥敏試驗和表現型確認的關鍵，但諸如新一代定序和聚合酵素鏈鎖反應等分子方法正擴大用於複雜病例的快速鑑定和表徵。自動化和手動工作流程中的檢測類型偏好反映了機構的優先事項。自動化平台有利於提高檢測的一致性並縮短週轉時間，而手動檢測可能在樣本量較小或資源有限的環境中繼續使用。細菌學檢測分為革蘭氏陰性菌和革蘭氏陽性菌檢測，真菌檢測涵蓋黴菌和酵母，而分枝桿菌檢測則需要特殊的處理方法。血漿和全血檢體類型會影響處理方案和設備相容性，而集中式和照護現場（包括床邊檢測和可攜式檢測）等交付方式則決定了檢測能力的分散式和集中式。這些細分視角構成了一個多維框架，可用於客製化產品開發、商業化和臨床應用策略。

影響美洲、歐洲、中東和非洲以及亞太地區技術採納、採購偏好和服務模式的區域動態和基礎設施因素

地理動態導致美洲、歐洲、中東和非洲以及亞太地區的需求促進因素和營運限制各不相同，這反映了各自不同的醫療基礎設施、報銷模式和區域供應鏈架構。在美洲，大型綜合醫療系統和對診斷管理的重視影響著人們對高效能自動化和互聯互通的偏好。在歐洲、中東和非洲，監管協調工作與不同的採購框架和基礎設施異質性並存，這為模組化解決方案提供了機遇，以應對不同的臨床環境。在亞太地區，快速發展的實驗室網路與成熟的卓越中心相結合，推動了人們對可擴展自動化和分子支持設備的濃厚興趣，以應對地方性感染和院內感染的挑戰。

不同地區的籌資策略在平衡資本支出和營運支出方面存在差異。資金雄厚的地區通常需要先進的分析設備和整合自動化系統來支援高通量工作流程，而資源有限的地區則更依賴人工或半自動化方法以及耐用耗材。隨著跨境物流和關稅制度進一步影響分銷策略，供應商和醫療系統必須考慮區域倉庫、區域合作夥伴關係和靈活的服務模式，以確保供應的可靠性。值得注意的是，抗菌素抗藥性監測、敗血症管理計畫和公共衛生報告等臨床重點會影響特定技術和檢測方法的應用。

競爭優勢源自於一體化的解決方案組合、強大的服務網路以及與實驗室工作流程和臨床重點一致的有針對性的創新。

在血液培養檢測生態系統中，產品可靠性、整合能力和服務卓越性將決定企業的競爭地位。擁有豐富耗材和儀器產品組合的領導企業，將透過提供端到端解決方案來降低供應商管理的複雜性並檢驗無縫工作流程，從而獲得優勢。投資於互通性、數據整合和以使用者為中心的設計，以最大限度地減少人工操作時間並簡化結果報告流程的企業，將增強其對高通量實驗室和醫院系統的價值提案。相反，專注於快速分子鑑定或高靈敏度檢測等細分技術領域的專業公司，可以在將先進診斷視為優先事項的參考中心和三級醫院中佔據戰略地位。

夥伴關係策略和通路模式也是區分不同競爭策略的關鍵因素。那些擁有強大的經銷商網路和本地技術支援的公司，能夠更好地服務於多元化的地域市場；而那些提供嵌入式服務項目、再貸款方案和按績效付費合約的公司，則可以緩解客戶的資金壓力。此外，在供應鏈中斷時期展現出透明度和應對力的公司，能夠與機構投資者建立信任和長期合作關係。整合自動化、分子輔助試劑和數位化報告功能的創新產品線能夠提升臨床和營運效益，而那些將研發投資與實際實驗室工作流程結合的企業，更有可能在採購決策中獲得優先考慮。

最終，一家公司的成功越來越取決於它能否提供可證明的營運效率、符合監管規定的績效以及可擴展的支援模式，以符合其多樣化實驗室客戶的臨床和財務目標。

為供應商和實驗室領導者提供可操作的策略重點，以提升診斷價值、營運韌性和以合作夥伴為中心的商業化模式。

產業領導者若想鞏固市場地位並提升臨床影響力，應著重投資於提高診斷價值和增強營運韌性這兩大目標。首先，應優先考慮能夠連接表現型培養和快速分子鑑定，並在現有實驗室工作流程限制下提供臨床可操作結果的解決方案。這樣做既能使機構及時為臨床醫生提供資訊，又能滿足下游表現型藥敏試驗的需求。其次，應投資於自動化和資訊科學，以減少人為操作差異並縮短週轉時間，同時確保技術應用配備完善的培訓和檢驗機制。

第三，我們透過多元化採購、區域倉儲和透明的庫存管理來建立供應鏈彈性。這些措施降低了關稅引發的成本轉移和物流瓶頸帶來的風險。第四，我們透過以結果為導向的服務產品與終端用戶互動，例如試劑租賃模式、試劑管理項目和績效保證型契約服務將供應商的激勵機制與實驗室的吞吐量和品質目標相結合。第五，我們尋求與臨床團隊的夥伴關係，並將診斷管理原則融入檢測演算法和報告格式，以加強檢測結果與治療決策之間的連結。最後，我們在產品設計中融入可擴展性，使我們的解決方案能夠適應門診中心、血庫、參考文獻實驗室和醫院系統，並支援與資本週期和臨床需求相適應的增量升級和模組化部署。

採用嚴謹的混合方法研究途徑，結合實務工作者訪談、技術文獻和檢驗步驟，以獲得實用、可複製的診斷見解。

本研究採用混合方法，綜合分析了與血液培養診斷相關的臨床、商業性和營運方面的見解。一級資訊來源包括對實驗室主任、採購負責人和臨床微生物學家的結構化訪談，以深入了解工作流程的限制、驗證實踐和臨床應用案例。二級資訊來源包括同行評審文獻、監管指南和製造商技術文檔，以確認其符合現行標準和預期績效。分析整合了產品類型、最終用戶、技術和地區的橫斷面比較和定性主題綜合，以識別一致的模式和差異化促進因素。

為提高可靠性，研究結果透過多通路資料進行三角驗證，並在專家評審會議上根據從業人員的回饋檢驗。調查方法的保障措施包括：在文獻和技術文件中清晰記錄納入標準，並仔細闡明技術定義，以區分傳統培養方法和分子輔助方法。此外，還概述了資料來源、訪談通訊協定和分析框架，以確保研究結果的可重複性，並允許相關人員質疑假設，並將研究結果應用於自身的實際操作環境中。這項綜合研究在強調實際應用價值的同時，也基於既定的實驗室實踐和當前的診斷趨勢，為策略規劃和營運最佳化提供了可靠的基礎。

整合臨床、營運和策略要務，指南血液培養診斷解決方案的有效部署和永續發展

血液培養診斷正處於曲折點，技術創新、供應鏈考量和臨床需求正在融合，重塑實驗室實踐。儘管傳統培養系統仍然是表現型藥敏試驗的基礎，但分子和自動化輔助技術正在重新定義人們對速度和診斷解析度的期望。這些互補的模式為混合診斷管道創造了機會，兼顧快速鑑定和全面的藥敏測定，從而改善血液管理和患者預後。在營運方面，實驗室在採用新平台時，必須應對與關稅相關的成本壓力、供應鏈波動以及整合和檢驗的要求。

強調互通性、在地供應鏈韌性和以結果為導向的服務模式的策略應對措施，最有可能有效維持績效和價值。針對不同終端使用者（從床邊即時檢測到高通量標準實驗室）的細微需求客製化產品系列，將使供應商和醫療機構能夠在控制整體營運成本的同時提高診斷效率。展望未來，連結製造商、實驗室負責人和臨床團隊的協作方式將加速技術進步轉化為可衡量的臨床效益，為疑似血流感染患者提供更安全、更快速、更有針對性的治療。

目錄

第1章：序言

第2章調查方法

第3章執行摘要

第4章 市場概覽

第5章 市場洞察

  • 將人工智慧驅動的病原體鑑定軟體整合到自動化血液培養平台中，以實現更快的診斷
  • 擴大快速分子血液培養檢測規模，以便在照護端檢測抗菌藥物抗藥性標記物
  • 引進連續監測血液培養系統以縮短加加護病房的檢測時間
  • 開發結合傳統培養方法的多重PCR檢測板，用於全面篩檢敗血症病原體。
  • 加強診斷公司與醫院之間的合作，以實施抗菌藥物管理計劃
  • 諸如體外診斷醫療器材法規（IVDR）等新的法規結構正在影響歐洲血液培養診斷的設計和檢驗。
  • 偏遠和資源匱乏的醫療機構對可攜式床邊血液培養設備的需求日益成長
  • 新冠疫情對醫院血液培養利用率及敗血症管理通訊協定的影響
  • 重點關注一次性血液培養瓶及輔助耗材的永續性和減少塑膠廢棄物。
  • 策略性併購推動領先血液培養系統製造商的整合

第6章美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章 血液培養檢測產品市場

  • 消耗品
    • 瓶子
    • 培養基
    • 試劑組
  • 裝置
    • 分析器
    • 自動化系統

第9章 依最終用戶分類的血液培養檢測市場

  • 門診治療中心
    • 獨立診所
    • 診所
  • 血庫
  • 診斷實驗室
    • 醫院實驗室
    • 獨立實驗室
  • 醫院和診所
    • 二級醫院
    • 三級醫院

第10章 按技術分類的血液培養檢測市場

  • 傳統的
  • 分子
    • 下一代定序
    • 聚合酵素鏈鎖反應

第11章 依檢測類型分類的血液培養檢測市場

  • 自動的
  • 手動的

第12章 按應用分類的血液培養檢測市場

  • 細菌
    • 革蘭氏陰性菌
    • 革蘭氏陽性菌
  • 真菌
    • 絲狀真菌
    • 酵母菌
  • 抗酸桿菌

第13章 依樣本類型分類的血液培養檢測市場

  • 電漿
  • 全血

第14章 血液培養檢測市場（依模式分類）

  • 中央實驗室
  • 照護現場
    • 床頭
    • 可攜式的

第15章 各地區血液培養檢測市場

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第16章 血液培養檢測市場（依集團分類）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第17章 各國血液培養檢測市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第18章 競爭格局

  • 2024年市佔率分析
  • FPNV定位矩陣，2024
  • 競爭分析
    • Becton Dickinson and Company
    • bioMerieux SA
    • Thermo Fisher Scientific Inc.
    • Siemens Healthineers AG
    • Sysmex Corporation
    • Accelerate Diagnostics, Inc.
    • bio-Rad Laboratories, Inc.
    • Sigma-Aldrich
    • Thermo Fisher Scientific Inc.
    • F. Hoffmann-La Roche
Product Code: MRR-035DA3C63737

The Blood Culture Test Market is projected to grow by USD 7.36 billion at a CAGR of 6.36% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 4.49 billion
Estimated Year [2025] USD 4.78 billion
Forecast Year [2032] USD 7.36 billion
CAGR (%) 6.36%

A concise orientation to the evolving clinical and operational significance of blood culture diagnostics within modern healthcare delivery systems

Blood culture testing remains a foundational diagnostic procedure for detecting bloodstream infections and guiding antimicrobial therapy. Advances in culture systems, automation, and molecular adjuncts have increased the clinical relevance and operational throughput of blood culture workflows, while laboratories continually balance speed, sensitivity, and cost in specimen processing. In clinical settings, timely detection directly influences patient outcomes by informing targeted therapy and reducing inappropriate antimicrobial exposure, making blood culture capability a critical component of acute care pathways.

In parallel, laboratory managers and procurement specialists must navigate a landscape shaped by technology convergence, supply chain dynamics, and evolving regulatory expectations. The integration of automated analyzers with front-end specimen handling and data connectivity has improved consistency and reduced hands-on time, yet it has also introduced new vendor interoperability and validation considerations. As healthcare systems prioritize diagnostic stewardship and laboratory efficiency, blood culture testing is experiencing both operational refinement and strategic reassessment across hospital systems, independent laboratories, and outpatient facilities.

This executive summary synthesizes current dynamics affecting clinical practice, technology adoption, and organizational investment decisions. It highlights how shifts in diagnostic paradigms, policy environments, and end-user requirements are reshaping procurement preferences and implementation strategies, with implications for clinical laboratories, device manufacturers, and healthcare administrators seeking to optimize diagnostic value across care continuums.

How innovation, automation, supply chain resilience, and diagnostic stewardship are jointly reshaping laboratory workflows and clinical pathways in blood culture testing

The diagnostic landscape for bloodstream infection detection is undergoing transformative shifts driven by technological innovation, workflow optimization, and a reimagining of laboratory roles within care pathways. Conventional culture techniques continue to provide essential phenotypic information, yet molecular platforms and rapid identification methods have expanded the clinician's toolkit, enabling earlier de-escalation of empiric therapy and enhanced antimicrobial stewardship. This technological diversification has prompted laboratories to re-evaluate test algorithms and to adopt hybrid approaches that leverage both culture and molecular modalities for complementary strengths.

Operationally, increased adoption of automation across pre-analytical and analytical stages is altering laboratory staffing models and throughput expectations. Automation reduces manual variability and supports higher sample volumes, but it also necessitates investments in training, validation, and informatics to ensure seamless integration. At the same time, supply chain resilience has emerged as a strategic priority. Laboratories and suppliers are exploring redundancy in sourcing consumables and diversifying logistics to mitigate disruptions, which in turn affects procurement cycles and inventory management practices.

Clinically, there is an intensified focus on diagnostic stewardship, driven by payer scrutiny and institutional quality initiatives. Diagnostic pathways are being redesigned to emphasize timely and accurate detection while avoiding unnecessary testing. This shift influences adoption patterns for both automated and manual testing modalities and underscores the importance of actionable reporting, result turnaround time, and linkage to clinical decision support systems. Taken together, these trends are not only reshaping laboratory operations but also creating new opportunities for vendors and health systems to collaborate on integrated solutions that deliver measurable clinical and economic value.

Assessment of tariff-driven procurement stressors and supply chain strategies that are influencing cost structures, sourcing decisions, and distribution models across blood culture diagnostics

Recent tariff developments and trade policy adjustments have created material downstream effects for clinical laboratories, manufacturers, and distributors involved in blood culture diagnostics. Increased import duties on certain laboratory equipment and consumables can raise landed costs, prompting procurement teams to reassess supplier portfolios and negotiate longer-term contracts to stabilize pricing. In response, manufacturers may explore regionalization of production, alternative sourcing strategies, or changes to product configurations to mitigate tariff exposure while preserving margin structures.

These dynamics influence procurement behavior across end users, with hospitals and independent laboratories weighing the trade-offs between unit cost, reliability of supply, and vendor support commitments. Some organizations may prioritize stocking larger inventories of critical consumables to buffer against price volatility, while others will seek service models that reduce capital expenditure and transfer supply risk to vendors through managed services or reagent-rental agreements. Moreover, increased costs can accelerate interest in automation and workflow efficiency initiatives as organizations seek to offset higher per-unit prices through labor savings and reduced waste.

At the same time, regulatory and customs complexities associated with tariff implementation can extend lead times and complicate product launch strategies for new analyzers and consumables. Manufacturers and distributors are therefore adapting distribution and logistics frameworks, enhancing visibility across supply chains, and collaborating with customers to develop contingency plans. Collectively, these changes encourage more strategic procurement planning, foster supplier diversification, and create incentives for supply chain transparency and regional manufacturing investment to reduce the cumulative impact of tariff-related cost pressures.

Integrated segmentation analysis outlining product, end-user, technological, test-type, application, sample type, and mode implications that shape adoption and procurement dynamics

A granular view across product categories reveals distinct considerations for consumables and instruments that shape adoption and purchasing behavior. Consumables, encompassing bottles, culture media, and reagent kits, drive recurring operating cost and are evaluated for lot-to-lot consistency, storage requirements, and compatibility with automated systems. Instruments, including analyzers and automation systems, require capital planning, integration with laboratory information systems, and long-term service agreements. Consequently, buying decisions often balance the predictability of consumable supply against the efficiency gains and validation burden associated with analyzer deployment.

End-user segmentation highlights that ambulatory care centers, blood banks, diagnostic laboratories, and hospitals and clinics each follow different operational models and procurement imperatives. Ambulatory care delivery is typically split between independent clinics and physician offices, which prioritize ease of use and compact footprint. Blood banks emphasize reliability and regulatory compliance, whereas diagnostic laboratories - including hospital-based labs and independent labs - focus on throughput, turnaround time, and interoperability. Secondary and tertiary hospitals within the hospital and clinic segment demand scalable solutions, with tertiary centers often integrating advanced identification technologies.

Technology choices between conventional and molecular methods determine diagnostic pathways. Conventional culture remains essential for susceptibility testing and phenotypic confirmation, while molecular approaches, such as next generation sequencing and polymerase chain reaction, are increasingly used for rapid identification and characterization in complex cases. Test type preferences between automated and manual workflows reflect institutional priorities: automated platforms favor consistency and reduced hands-on time, whereas manual testing may persist in low-volume or resource-constrained settings. Application-specific requirements further differentiate use cases, with bacterial testing divided into gram-negative and gram-positive targets, fungal testing addressing filamentous fungi and yeast, and mycobacterial assays requiring specialized processing. Sample type considerations between plasma and whole blood influence processing protocols and instrument compatibility, and mode of delivery, whether central laboratory or point of care, including bedside and portable options, drives decisions about decentralization versus consolidated testing capacity. Together, these segmentation lenses provide a multidimensional framework for aligning product development, commercialization, and clinical implementation strategies.

Regional dynamics and infrastructure factors that steer technology adoption, procurement preferences, and service models across the Americas, Europe Middle East & Africa, and Asia-Pacific landscapes

Geographic dynamics create differentiated demand drivers and operational constraints across the Americas, Europe, Middle East & Africa, and Asia-Pacific regions, each reflecting unique healthcare infrastructure, reimbursement models, and regional supply chain architectures. In the Americas, large integrated healthcare systems and a focus on diagnostic stewardship influence preferences for high-throughput automation and connectivity, while independent laboratories drive decentralized service provision. Within Europe, Middle East & Africa, regulatory harmonization efforts coexist with varied purchasing frameworks and infrastructure heterogeneity, creating opportunities for modular solutions that accommodate diverse clinical settings. The Asia-Pacific region presents a mix of rapidly developing laboratory networks alongside mature centers of excellence, with considerable interest in scalable automation and molecular adjuncts to address both endemic and hospital-acquired infection challenges.

Regional procurement strategies differ in how they balance capital investment with operational expenditures. In well-capitalized systems, there is often appetite for advanced analyzers and integrated automation to support high-volume workflows, whereas in regions with resource constraints, manual or semi-automated approaches and durable consumables retain relevance. Cross-border logistics and tariff regimes further shape distribution strategies, prompting vendors and health systems to consider regional warehousing, local partnerships, and flexible service models to maintain supply reliability. Importantly, clinical priorities such as antimicrobial resistance surveillance, sepsis management programs, and public health reporting influence uptake of specific technologies and assays, leading to regionally tailored product roadmaps and support services that align with local clinical imperatives.

Competitive differentiation emerges from integrated solution portfolios, robust service networks, and targeted innovations that align with laboratory workflows and clinical priorities

Competitive positioning in the blood culture testing ecosystem is shaped by companies that excel in product reliability, integration capabilities, and service excellence. Leaders with broad portfolios across consumables and instrumentation gain advantage by offering end-to-end solutions that reduce the complexity of supplier management and validate seamless workflows. Organizations that invest in interoperability, data integration, and user-centered design to minimize hands-on time and streamline result reporting strengthen their value proposition to high-volume laboratories and hospital systems. Conversely, specialized companies that focus on niche technology areas-such as rapid molecular identification or high-sensitivity detection-can secure strategic placements within reference centers and tertiary institutions where advanced diagnostics are prioritized.

Partnership strategies and channel models also differentiate competitive approaches. Firms that cultivate robust distributor networks and local technical support are better positioned to serve diverse geographies, while those that offer embedded service programs, reagent-rental options, or outcome-linked contracting can alleviate capital constraints for customers. Additionally, companies that demonstrate supply chain transparency and responsiveness during periods of disruption build trust and long-term relationships with institutional buyers. Innovation pipelines that integrate automation, molecular adjuncts, and digital reporting capabilities offer incremental clinical and operational benefits, and organizations that align R&D investments with real-world laboratory workflows will likely secure preferential consideration in procurement decisions.

Ultimately, company success is increasingly tied to the ability to deliver demonstrable operational efficiencies, regulatory-compliant performance, and scalable support models that align with the clinical and financial objectives of diverse laboratory customers.

Actionable strategic priorities for vendors and laboratory leaders to enhance diagnostic value, operational resilience, and partner-focused commercialization models

Industry leaders seeking to strengthen market position and clinical impact should align investments with the twin objectives of improving diagnostic value and enhancing operational resilience. First, prioritize solutions that bridge phenotypic culture and rapid molecular identification to deliver clinically actionable results within the constraints of existing laboratory workflows. By doing so, organizations can support clinicians with timely information while preserving the downstream need for phenotypic susceptibility testing. Second, invest in automation and informatics that reduce manual variability and shorten turnaround times, ensuring that technology deployments are accompanied by robust training and validation programs to secure adoption.

Third, build supply chain flexibility through diversified sourcing, regional warehousing, and transparent inventory management. Such measures reduce vulnerability to tariff-induced cost shifts and logistical bottlenecks. Fourth, engage end users through outcome-focused service offerings, including reagent-rental models, managed reagent programs, and performance-based contracting that align vendor incentives with laboratory throughput and quality objectives. Fifth, pursue partnerships with clinical teams to embed diagnostic stewardship principles into testing algorithms and reporting formats, thereby strengthening the linkage between laboratory outputs and therapeutic decision-making. Finally, incorporate scalability into product design so that solutions are adaptable across ambulatory centers, blood banks, reference labs, and hospital systems, supporting phased upgrades and modular deployments that match capital cycles and clinical demand.

A rigorous mixed-methods research approach combining practitioner interviews, technical literature, and validation steps to produce actionable and reproducible diagnostic insights

This research employed a mixed-methods approach to synthesize clinical, commercial, and operational insights relevant to blood culture diagnostics. Primary inputs included structured interviews with laboratory directors, procurement officers, and clinical microbiologists, providing contextual understanding of workflow constraints, validation practices, and clinical use cases. Secondary sources comprised peer-reviewed literature, regulatory guidance, and manufacturer technical documentation to ensure alignment with current standards and performance expectations. The analysis integrated qualitative thematic synthesis with cross-sectional comparisons across product categories, end users, technologies, and geographic regions to identify consistent patterns and differentiated drivers.

To enhance reliability, findings were triangulated through multiple data streams and validated against practitioner feedback during expert review sessions. Methodological safeguards included explicit documentation of inclusion criteria for literature and technical documents, and careful delineation of technology definitions to distinguish conventional culture processes from molecular adjuncts. The approach prioritized reproducibility by outlining data sources, interview protocols, and analytic frameworks, enabling stakeholders to interrogate assumptions and adapt insights to their specific operational contexts. While this synthesis emphasizes practical implications, it remains grounded in established laboratory practice and contemporary diagnostic trends, providing a credible foundation for strategic planning and operational optimization.

Synthesis of clinical, operational, and strategic imperatives that converge to guide effective adoption and sustainable deployment of blood culture diagnostic solutions

Blood culture diagnostics are at an inflection point where technological innovation, supply chain considerations, and clinical priorities converge to reshape laboratory practice. Conventional culture systems remain central for phenotype-based susceptibility testing, while molecular and automated adjuncts are redefining expectations for speed and diagnostic resolution. These complementary modalities create opportunities for hybrid diagnostic pathways that balance rapid identification with comprehensive susceptibility determination, thereby improving stewardship and patient outcomes. Operationally, laboratories must navigate tariff-related cost pressures, supply chain variability, and the demands of integration and validation when adopting new platforms.

Strategic responses that emphasize interoperability, regional supply resilience, and outcome-focused service models will be most effective in sustaining performance and value. By aligning product portfolios with the nuanced needs of different end users - from bedside point-of-care contexts to high-throughput reference laboratories - vendors and healthcare organizations can enhance diagnostic impact while managing total cost of operation. Looking ahead, collaborative approaches that connect manufacturers, laboratory leaders, and clinical teams will accelerate the translation of technological advances into measurable clinical benefits, supporting safer, faster, and more targeted care for patients with suspected bloodstream infections.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Integration of AI driven pathogen identification software into automated blood culture platforms enabling faster diagnosis
  • 5.2. Expansion of rapid molecular blood culture assays to detect antimicrobial resistance markers at point of care
  • 5.3. Adoption of continuous monitoring blood culture systems reducing time to detection in critical care settings
  • 5.4. Growth of multiplex PCR panels paired with traditional culture for comprehensive sepsis pathogen screening
  • 5.5. Increasing collaboration between diagnostic companies and hospitals to implement antibiotic stewardship programs
  • 5.6. Emerging regulatory frameworks like IVDR influencing design and validation of blood culture diagnostics in Europe
  • 5.7. Rising demand for portable point of care blood culture devices in remote and resource limited healthcare facilities
  • 5.8. Impact of COVID 19 pandemic on blood culture utilization and sepsis management protocols in hospitals
  • 5.9. Focus on sustainability and reduced plastic waste in single use blood culture bottles and ancillary consumables
  • 5.10. Strategic mergers and acquisitions driving consolidation among leading blood culture system manufacturers

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Blood Culture Test Market, by Product

  • 8.1. Consumables
    • 8.1.1. Bottles
    • 8.1.2. Culture Media
    • 8.1.3. Reagent Kits
  • 8.2. Instruments
    • 8.2.1. Analyzers
    • 8.2.2. Automation Systems

9. Blood Culture Test Market, by End User

  • 9.1. Ambulatory Care Centers
    • 9.1.1. Independent Clinics
    • 9.1.2. Physician Offices
  • 9.2. Blood Banks
  • 9.3. Diagnostic Laboratories
    • 9.3.1. Hospital Based Labs
    • 9.3.2. Independent Labs
  • 9.4. Hospitals & Clinics
    • 9.4.1. Secondary Hospitals
    • 9.4.2. Tertiary Hospitals

10. Blood Culture Test Market, by Technology

  • 10.1. Conventional
  • 10.2. Molecular
    • 10.2.1. Next Generation Sequencing
    • 10.2.2. Polymerase Chain Reaction

11. Blood Culture Test Market, by Test Type

  • 11.1. Automated
  • 11.2. Manual

12. Blood Culture Test Market, by Application

  • 12.1. Bacterial
    • 12.1.1. Gram Negative
    • 12.1.2. Gram Positive
  • 12.2. Fungal
    • 12.2.1. Filamentous Fungi
    • 12.2.2. Yeast
  • 12.3. Mycobacterial

13. Blood Culture Test Market, by Sample Type

  • 13.1. Plasma
  • 13.2. Whole Blood

14. Blood Culture Test Market, by Mode

  • 14.1. Central Lab
  • 14.2. Point Of Care
    • 14.2.1. Bedside
    • 14.2.2. Portable

15. Blood Culture Test Market, by Region

  • 15.1. Americas
    • 15.1.1. North America
    • 15.1.2. Latin America
  • 15.2. Europe, Middle East & Africa
    • 15.2.1. Europe
    • 15.2.2. Middle East
    • 15.2.3. Africa
  • 15.3. Asia-Pacific

16. Blood Culture Test Market, by Group

  • 16.1. ASEAN
  • 16.2. GCC
  • 16.3. European Union
  • 16.4. BRICS
  • 16.5. G7
  • 16.6. NATO

17. Blood Culture Test Market, by Country

  • 17.1. United States
  • 17.2. Canada
  • 17.3. Mexico
  • 17.4. Brazil
  • 17.5. United Kingdom
  • 17.6. Germany
  • 17.7. France
  • 17.8. Russia
  • 17.9. Italy
  • 17.10. Spain
  • 17.11. China
  • 17.12. India
  • 17.13. Japan
  • 17.14. Australia
  • 17.15. South Korea

18. Competitive Landscape

  • 18.1. Market Share Analysis, 2024
  • 18.2. FPNV Positioning Matrix, 2024
  • 18.3. Competitive Analysis
    • 18.3.1. Becton Dickinson and Company
    • 18.3.2. bioMerieux SA
    • 18.3.3. Thermo Fisher Scientific Inc.
    • 18.3.4. Siemens Healthineers AG
    • 18.3.5. Sysmex Corporation
    • 18.3.6. Accelerate Diagnostics, Inc.
    • 18.3.7. bio-Rad Laboratories, Inc.
    • 18.3.8. Sigma-Aldrich
    • 18.3.9. Thermo Fisher Scientific Inc.
    • 18.3.10. F. Hoffmann-La Roche

LIST OF FIGURES

  • FIGURE 1. GLOBAL BLOOD CULTURE TEST MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY PRODUCT, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY PRODUCT, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY TECHNOLOGY, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY TECHNOLOGY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY TEST TYPE, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY TEST TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY APPLICATION, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY SAMPLE TYPE, 2024 VS 2032 (%)
  • FIGURE 13. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY SAMPLE TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY MODE, 2024 VS 2032 (%)
  • FIGURE 15. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY MODE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. AMERICAS BLOOD CULTURE TEST MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. NORTH AMERICA BLOOD CULTURE TEST MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. LATIN AMERICA BLOOD CULTURE TEST MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA BLOOD CULTURE TEST MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. EUROPE BLOOD CULTURE TEST MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. MIDDLE EAST BLOOD CULTURE TEST MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. AFRICA BLOOD CULTURE TEST MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. ASIA-PACIFIC BLOOD CULTURE TEST MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. ASEAN BLOOD CULTURE TEST MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. GCC BLOOD CULTURE TEST MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. EUROPEAN UNION BLOOD CULTURE TEST MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. BRICS BLOOD CULTURE TEST MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 30. G7 BLOOD CULTURE TEST MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 31. NATO BLOOD CULTURE TEST MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 32. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 33. BLOOD CULTURE TEST MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 34. BLOOD CULTURE TEST MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. BLOOD CULTURE TEST MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL BLOOD CULTURE TEST MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL BLOOD CULTURE TEST MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY PRODUCT, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY CONSUMABLES, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY CONSUMABLES, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY CONSUMABLES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY CONSUMABLES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY CONSUMABLES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY CONSUMABLES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY CONSUMABLES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY CONSUMABLES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY BOTTLES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY BOTTLES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY BOTTLES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY BOTTLES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY BOTTLES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY BOTTLES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY CULTURE MEDIA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY CULTURE MEDIA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY CULTURE MEDIA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY CULTURE MEDIA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY CULTURE MEDIA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY CULTURE MEDIA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY REAGENT KITS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY REAGENT KITS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY REAGENT KITS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY REAGENT KITS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY REAGENT KITS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY REAGENT KITS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY INSTRUMENTS, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY INSTRUMENTS, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY INSTRUMENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY INSTRUMENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY INSTRUMENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY INSTRUMENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY INSTRUMENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY INSTRUMENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY ANALYZERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY ANALYZERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY ANALYZERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY ANALYZERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY ANALYZERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY ANALYZERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY AUTOMATION SYSTEMS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY AUTOMATION SYSTEMS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY AUTOMATION SYSTEMS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY AUTOMATION SYSTEMS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY AUTOMATION SYSTEMS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY AUTOMATION SYSTEMS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY AMBULATORY CARE CENTERS, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY AMBULATORY CARE CENTERS, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY AMBULATORY CARE CENTERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY AMBULATORY CARE CENTERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY AMBULATORY CARE CENTERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY AMBULATORY CARE CENTERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY AMBULATORY CARE CENTERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY AMBULATORY CARE CENTERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY INDEPENDENT CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY INDEPENDENT CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY INDEPENDENT CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY INDEPENDENT CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY INDEPENDENT CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY INDEPENDENT CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY PHYSICIAN OFFICES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY PHYSICIAN OFFICES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY PHYSICIAN OFFICES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY PHYSICIAN OFFICES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY PHYSICIAN OFFICES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY PHYSICIAN OFFICES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY BLOOD BANKS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY BLOOD BANKS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY BLOOD BANKS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY BLOOD BANKS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY BLOOD BANKS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY BLOOD BANKS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY HOSPITAL BASED LABS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY HOSPITAL BASED LABS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY HOSPITAL BASED LABS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY HOSPITAL BASED LABS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY HOSPITAL BASED LABS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY HOSPITAL BASED LABS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY INDEPENDENT LABS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY INDEPENDENT LABS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY INDEPENDENT LABS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY INDEPENDENT LABS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY INDEPENDENT LABS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY INDEPENDENT LABS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY HOSPITALS & CLINICS, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY HOSPITALS & CLINICS, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY HOSPITALS & CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY HOSPITALS & CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY HOSPITALS & CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY HOSPITALS & CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY SECONDARY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY SECONDARY HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY SECONDARY HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY SECONDARY HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY SECONDARY HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY SECONDARY HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY TERTIARY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY TERTIARY HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY TERTIARY HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY TERTIARY HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY TERTIARY HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY TERTIARY HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY CONVENTIONAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY CONVENTIONAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY CONVENTIONAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY CONVENTIONAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY CONVENTIONAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY CONVENTIONAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY MOLECULAR, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY MOLECULAR, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY MOLECULAR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY MOLECULAR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY MOLECULAR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY MOLECULAR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY MOLECULAR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY MOLECULAR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY AUTOMATED, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY AUTOMATED, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY AUTOMATED, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY AUTOMATED, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY AUTOMATED, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY AUTOMATED, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY MANUAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY MANUAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY MANUAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY MANUAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY MANUAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY MANUAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY BACTERIAL, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY BACTERIAL, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY BACTERIAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY BACTERIAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY BACTERIAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY BACTERIAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY BACTERIAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY BACTERIAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY GRAM NEGATIVE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY GRAM NEGATIVE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY GRAM NEGATIVE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY GRAM NEGATIVE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY GRAM NEGATIVE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY GRAM NEGATIVE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 179. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY GRAM POSITIVE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY GRAM POSITIVE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 181. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY GRAM POSITIVE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 182. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY GRAM POSITIVE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 183. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY GRAM POSITIVE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 184. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY GRAM POSITIVE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 185. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY FUNGAL, 2018-2024 (USD MILLION)
  • TABLE 186. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY FUNGAL, 2025-2032 (USD MILLION)
  • TABLE 187. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY FUNGAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 188. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY FUNGAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 189. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY FUNGAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 190. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY FUNGAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 191. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY FUNGAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 192. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY FUNGAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 193. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY FILAMENTOUS FUNGI, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 194. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY FILAMENTOUS FUNGI, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 195. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY FILAMENTOUS FUNGI, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 196. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY FILAMENTOUS FUNGI, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 197. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY FILAMENTOUS FUNGI, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 198. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY FILAMENTOUS FUNGI, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 199. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY YEAST, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 200. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY YEAST, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 201. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY YEAST, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 202. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY YEAST, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 203. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY YEAST, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 204. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY YEAST, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 205. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY MYCOBACTERIAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 206. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY MYCOBACTERIAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 207. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY MYCOBACTERIAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 208. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY MYCOBACTERIAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 209. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY MYCOBACTERIAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 210. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY MYCOBACTERIAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 211. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
  • TABLE 212. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY SAMPLE TYPE, 2025-2032 (USD MILLION)
  • TABLE 213. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY PLASMA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 214. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY PLASMA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 215. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY PLASMA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 216. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY PLASMA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 217. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY PLASMA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 218. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY PLASMA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 219. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY WHOLE BLOOD, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 220. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY WHOLE BLOOD, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 221. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY WHOLE BLOOD, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 222. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY WHOLE BLOOD, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 223. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY WHOLE BLOOD, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 224. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY WHOLE BLOOD, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 225. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY MODE, 2018-2024 (USD MILLION)
  • TABLE 226. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY MODE, 2025-2032 (USD MILLION)
  • TABLE 227. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY CENTRAL LAB, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 228. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY CENTRAL LAB, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 229. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY CENTRAL LAB, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 230. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY CENTRAL LAB, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 231. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY CENTRAL LAB, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 232. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY CENTRAL LAB, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 233. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY POINT OF CARE, 2018-2024 (USD MILLION)
  • TABLE 234. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY POINT OF CARE, 2025-2032 (USD MILLION)
  • TABLE 235. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY POINT OF CARE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 236. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY POINT OF CARE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 237. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY POINT OF CARE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 238. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY POINT OF CARE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 239. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY POINT OF CARE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 240. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY POINT OF CARE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 241. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY BEDSIDE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 242. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY BEDSIDE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 243. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY BEDSIDE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 244. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY BEDSIDE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 245. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY BEDSIDE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 246. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY BEDSIDE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 247. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY PORTABLE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 248. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY PORTABLE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 249. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY PORTABLE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 250. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY PORTABLE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 251. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY PORTABLE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 252. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY PORTABLE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 253. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 254. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 255. AMERICAS BLOOD CULTURE TEST MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 256. AMERICAS BLOOD CULTURE TEST MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 257. AMERICAS BLOOD CULTURE TEST MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 258. AMERICAS BLOOD CULTURE TEST MARKET SIZE, BY PRODUCT, 2025-2032 (USD MILLION)
  • TABLE 259. AMERICAS BLOOD CULTURE TEST MARKET SIZE, BY CONSUMABLES, 2018-2024 (USD MILLION)
  • TABLE 260. AMERICAS BLOOD CULTURE TEST MARKET SIZE, BY CONSUMABLES, 2025-2032 (USD MILLION)
  • TABLE 261. AMERICAS BLOOD CULTURE TEST MARKET SIZE, BY INSTRUMENTS, 2018-2024 (USD MILLION)
  • TABLE 262. AMERICAS BLOOD CULTURE TEST MARKET SIZE, BY INSTRUMENTS, 2025-2032 (USD MILLION)
  • TABLE 263. AMERICAS BLOOD CULTURE TEST MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 264. AMERICAS BLOOD CULTURE TEST MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 265. AMERICAS BLOOD CULTURE TEST MARKET SIZE, BY AMBULATORY CARE CENTERS, 2018-2024 (USD MILLION)
  • TABLE 266. AMERICAS BLOOD CULTURE TEST MARKET SIZE, BY AMBULATORY CARE CENTERS, 2025-2032 (USD MILLION)
  • TABLE 267. AMERICAS BLOOD CULTURE TEST MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2024 (USD MILLION)
  • TABLE 268. AMERICAS BLOOD CULTURE TEST MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2025-2032 (USD MILLION)
  • TABLE 269. AMERICAS BLOOD CULTURE TEST MARKET SIZE, BY HOSPITALS & CLINICS, 2018-2024 (USD MILLION)
  • TABLE 270. AMERICAS BLOOD CULTURE TEST MARKET SIZE, BY HOSPITALS & CLINICS, 2025-2032 (USD MILLION)
  • TABLE 271. AMERICAS BLOOD CULTURE TEST MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 272. AMERICAS BLOOD CULTURE TEST MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 273. AMERICAS BLOOD CULTURE TEST MARKET SIZE, BY MOLECULAR, 2018-2024 (USD MILLION)
  • TABLE 274. AMERICAS BLOOD CULTURE TEST MARKET SIZE, BY MOLECULAR, 2025-2032 (USD MILLION)
  • TABLE 275. AMERICAS BLOOD CULTURE TEST MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 276. AMERICAS BLOOD CULTURE TEST MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
  • TABLE 277. AMERICAS BLOOD CULTURE TEST MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 278. AMERICAS BLOOD CULTURE TEST MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 279. AMERICAS BLOOD CULTURE TEST MARKET SIZE, BY BACTERIAL, 2018-2024 (USD MILLION)
  • TABLE 280. AMERICAS BLOOD CULTURE TEST MARKET SIZE, BY BACTERIAL, 2025-2032 (USD MILLION)
  • TABLE 281. AMERICAS BLOOD CULTURE TEST MARKET SIZE, BY FUNGAL, 2018-2024 (USD MILLION)
  • TABLE 282. AMERICAS BLOOD CULTURE TEST MARKET SIZE, BY FUNGAL, 2025-2032 (USD MILLION)
  • TABLE 283. AMERICAS BLOOD CULTURE TEST MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
  • TABLE 284. AMERICAS BLOOD CULTURE TEST MARKET SIZE, BY SAMPLE TYPE, 2025-2032 (USD MILLION)
  • TABLE 285. AMERICAS BLOOD CULTURE TEST MARKET SIZE, BY MODE, 2018-2024 (USD MILLION)
  • TABLE 286. AMERICAS BLOOD CULTURE TEST MARKET SIZE, BY MODE, 2025-2032 (USD MILLION)
  • TABLE 287. AMERICAS BLOOD CULTURE TEST MARKET SIZE, BY POINT OF CARE, 2018-2024 (USD MILLION)
  • TABLE 288. AMERICAS BLOOD CULTURE TEST MARKET SIZE, BY POINT OF CARE, 2025-2032 (USD MILLION)
  • TABLE 289. NORTH AMERICA BLOOD CULTURE TEST MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 290. NORTH AMERICA BLOOD CULTURE TEST MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 291. NORTH AMERICA BLOOD CULTURE TEST MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 292. NORTH AMERICA BLOOD CULTURE TEST MARKET SIZE, BY PRODUCT, 2025-2032 (USD MILLION)
  • TABLE 293. NORTH AMERICA BLOOD CULTURE TEST MARKET SIZE, BY CONSUMABLES, 2018-2024 (USD MILLION)
  • TABLE 294. NORTH AMERICA BLOOD CULTURE TEST MARKET SIZE, BY CONSUMABLES, 2025-2032 (USD MILLION)
  • TABLE 295. NORTH AMERICA BLOOD CULTURE TEST MARKET SIZE, BY INSTRUMENTS, 2018-2024 (USD MILLION)
  • TABLE 296. NORTH AMERICA BLOOD CULTURE TEST MARKET SIZE, BY INSTRUMENTS, 2025-2032 (USD MILLION)
  • TABLE 297. NORTH AMERICA BLOOD CULTURE TEST MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 298. NORTH AMERICA BLOOD CULTURE TEST MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 299. NORTH AMERICA BLOOD CULTURE TEST MARKET SIZE, BY AMBULATORY CARE CENTERS, 2018-2024 (USD MILLION)
  • TABLE 300. NORTH AMERICA BLOOD CULTURE TEST MARKET SIZE, BY AMBULATORY CARE CENTERS, 2025-2032 (USD MILLION)
  • TABLE 301. NORTH AMERICA BLOOD CULTURE TEST MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2024 (USD MILLION)
  • TABLE 302. NORTH AMERICA BLOOD CULTURE TEST MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2025-2032 (USD MILLION)
  • TABLE 303. NORTH AMERICA BLOOD CULTURE TEST MARKET SIZE, BY HOSPITALS & CLINICS, 2018-2024 (USD MILLION)
  • TABLE 304. NORTH AMERICA BLOOD CULTURE TEST MARKET SIZE, BY HOSPITALS & CLINICS, 2025-2032 (USD MILLION)
  • TABLE 305. NORTH AMERICA BLOOD CULTURE TEST MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 306. NORTH AMERICA BLOOD CULTURE TEST MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 307. NORTH AMERICA BLOOD CULTURE TEST MARKET SIZE, BY MOLECULAR, 2018-2024 (USD MILLION)
  • TABLE 308. NORTH AMERICA BLOOD CULTURE TEST MARKET SIZE, BY MOLECULAR, 2025-2032 (USD MILLION)
  • TABLE 309. NORTH AMERICA BLOOD CULTURE TEST MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 310. NORTH AMERICA BLOOD CULTURE TEST MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
  • TABLE 311. NORTH AMERICA BLOOD CULTURE TEST MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 312. NORTH AMERICA BLOOD CULTURE TEST MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 313. NORTH AMERICA BLOOD CULTURE TEST MARKET SIZE, BY BACTERIAL, 2018-2024 (USD MILLION)
  • TABLE 314. NORTH AMERICA BLOOD CULTURE TEST MARKET SIZE, BY BACTERIAL, 2025-2032 (USD MILLION)
  • TABLE 315. NORTH AMERICA BLOOD CULTURE TEST MARKET SIZE, BY FUNGAL, 2018-2024 (USD MILLION)
  • TABLE 316. NORTH AMERICA BLOOD CULTURE TEST MARKET SIZE, BY FUNGAL, 2025-2032 (USD MILLION)
  • TABLE 317. NORTH AMERICA BLOOD CULTURE TEST MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
  • TABLE 318. NORTH AMERICA BLOOD CULTURE TEST MARKET SIZE, BY SAMPLE TYPE, 2025-2032 (USD MILLION)
  • TABLE 319. NORTH AMERICA BLOOD CULTURE TEST MARKET SIZE, BY MODE, 2018-2024 (USD MILLION)
  • TABLE 320. NORTH AMERICA BLOOD CULTURE TEST MARKET SIZE, BY MODE, 2025-2032 (USD MILLION)
  • TABLE 321. NORTH AMERICA BLOOD CULTURE TEST MARKET SIZE, BY POINT OF CARE, 2018-2024 (USD MILLION)
  • TABLE 322. NORTH AMERICA BLOOD CULTURE TEST MARKET SIZE, BY POINT OF CARE, 2025-2032 (USD MILLION)
  • TABLE 323. LATIN AMERICA BLOOD CULTURE TEST MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 324. LATIN AMERICA BLOOD CULTURE TEST MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 325. LATIN AMERICA BLOOD CULTURE TEST MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 326. LATIN AMERICA BLOOD CULTURE TEST MARKET SIZE, BY PRODUCT, 2025-2032 (USD MILLION)
  • TABLE 327. LATIN AMERICA BLOOD CULTURE TEST MARKET SIZE, BY CONSUMABLES, 2018-2024 (USD MILLION)
  • TABLE 328. LATIN AMERICA BLOOD CULTURE TEST MARKET SIZE, BY CONSUMABLES, 2025-2032 (USD MILLION)
  • TABLE 329. LATIN AMERICA BLOOD CULTURE TEST MARKET SIZE, BY INSTRUMENTS, 2018-2024 (USD MILLION)
  • TABLE 330. LATIN AMERICA BLOOD CULTURE TEST MARKET SIZE, BY INSTRUMENTS, 2025-2032 (USD